Ironshore

Ironshore Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of therapies for Attention Deficit Hyperactivity Disorder (ADHD). As a subsidiary of Highland Therapeutics, the company utilizes the proprietary DELEXIS drug delivery platform to create medications with unique pharmacokinetic profiles. Their lead product, Jornay PM (methylphenidate), is the first ADHD stimulant designed for evening administration to provide symptom control upon awakening and throughout the following day. This innovative approach aims to address the significant unmet need for morning symptom management in patients with ADHD. Ironshore is headquartered in North Carolina and continues to expand its portfolio of CNS-focused treatments.